TY - JOUR
T1 - Estrogen induces the expression of EBV lytic protein ZEBRA, a marker of poor prognosis in nasopharyngeal carcinoma
AU - Dochi, Hirotomo
AU - Kondo, Satoru
AU - Murata, Takayuki
AU - Fukuyo, Masaki
AU - Nanbo, Asuka
AU - Wakae, Kousho
AU - Jiang, Wen Ping
AU - Hamabe-Horiike, Toshihide
AU - Tanaka, Mariko
AU - Nishiuchi, Takumi
AU - Mizokami, Harue
AU - Moriyama-Kita, Makiko
AU - Kobayashi, Eiji
AU - Hirai, Nobuyuki
AU - Komori, Takeshi
AU - Ueno, Takayoshi
AU - Nakanishi, Yosuke
AU - Hatano, Miyako
AU - Endo, Kazuhira
AU - Sugimoto, Hisashi
AU - Wakisaka, Naohiro
AU - Juang, Shin Hun
AU - Muramatsu, Masamichi
AU - Kaneda, Atsushi
AU - Yoshizaki, Tomokazu
N1 - Publisher Copyright:
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2022/8
Y1 - 2022/8
N2 - Several epidemiological studies have suggested that Epstein–Barr virus (EBV) lytic infection is essential for the development of nasopharyngeal carcinoma (NPC), as the elevation of antibody titers against EBV lytic proteins is a common feature of NPC. Although ZEBRA protein is a key trigger for the initiation of lytic infection, whether its expression affects the prognosis and pathogenesis of NPC remains unclear. In this study, 64 NPC biopsy specimens were analyzed using immunohistochemistry. We found that ZEBRA was significantly associated with a worsening of progression-free survival in NPC (adjusted hazard ratio, 3.58; 95% confidence interval, 1.08–11.87; p = 0.037). Moreover, ZEBRA expression positively correlated with key endocrinological proteins, estrogen receptor α, and aromatase. The transcriptional level of ZEBRA is activated by estrogen in an estrogen receptor α-dependent manner, resulting in an increase in structural gene expression levels and extracellular virus DNA copy number in NPC cell lines, reminiscent of lytic infection. Interestingly, it did not suppress cellular proliferation or increase apoptosis, in contrast with cells treated with 12-O-tetradecanoylphorbol-13-acetate and sodium butyrate, indicating that viral production induced by estrogen is not a cell lytic phenomenon. Our results suggest that intratumoral estrogen overproduced by aromatase could induce ZEBRA expression and EBV reactivation, contributing to the progression of NPC.
AB - Several epidemiological studies have suggested that Epstein–Barr virus (EBV) lytic infection is essential for the development of nasopharyngeal carcinoma (NPC), as the elevation of antibody titers against EBV lytic proteins is a common feature of NPC. Although ZEBRA protein is a key trigger for the initiation of lytic infection, whether its expression affects the prognosis and pathogenesis of NPC remains unclear. In this study, 64 NPC biopsy specimens were analyzed using immunohistochemistry. We found that ZEBRA was significantly associated with a worsening of progression-free survival in NPC (adjusted hazard ratio, 3.58; 95% confidence interval, 1.08–11.87; p = 0.037). Moreover, ZEBRA expression positively correlated with key endocrinological proteins, estrogen receptor α, and aromatase. The transcriptional level of ZEBRA is activated by estrogen in an estrogen receptor α-dependent manner, resulting in an increase in structural gene expression levels and extracellular virus DNA copy number in NPC cell lines, reminiscent of lytic infection. Interestingly, it did not suppress cellular proliferation or increase apoptosis, in contrast with cells treated with 12-O-tetradecanoylphorbol-13-acetate and sodium butyrate, indicating that viral production induced by estrogen is not a cell lytic phenomenon. Our results suggest that intratumoral estrogen overproduced by aromatase could induce ZEBRA expression and EBV reactivation, contributing to the progression of NPC.
UR - http://www.scopus.com/inward/record.url?scp=85132695166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132695166&partnerID=8YFLogxK
U2 - 10.1111/cas.15440
DO - 10.1111/cas.15440
M3 - Article
C2 - 35633182
AN - SCOPUS:85132695166
SN - 1347-9032
VL - 113
SP - 2862
EP - 2877
JO - Cancer science
JF - Cancer science
IS - 8
ER -